BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 35910232)

  • 1. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Expression of the
    Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
    Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 8. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
    Li L; Feng Q; Wang X
    Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Yang W; Liu Z; Liu T
    Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
    Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma.
    Liu J; Li W; Wu L
    Front Pharmacol; 2022; 13():950156. PubMed ID: 36046831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
    Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
    Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
    Dong X; Liu T; Li Z; Zhai Y
    Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
    Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
    Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
    [No Abstract]   [Full Text] [Related]  

  • 17. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.
    Ye B; Shi J; Kang H; Oyebamiji O; Hill D; Yu H; Ness S; Ye F; Ping J; He J; Edwards J; Zhao YY; Guo Y
    RNA Biol; 2020 Nov; 17(11):1666-1673. PubMed ID: 31607216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.